CORDIS
EU research results

CORDIS

English EN
Biomarker Enterprise to Attack DKD - Sofia ref.: 115974

Biomarker Enterprise to Attack DKD - Sofia ref.: 115974

Objective

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent or cure DKD, the few existing treatments have limited effect and very few alternative therapies have emerged in the past years. Lack of new predictive and prognostic biomarkers for a more accurate patient stratification, limited access to kidney tissue from patients at various stages of DKD as well as novel model systems to better understand the pathogenesis of the disease, are likely reasons for the stagnating development of new treatments.

The BEAt-DKD consortium combines outstanding basic and translational researchers in nephropathy, diabetes, kidney model systems, imaging techniques and systems biology, and includes leaders of diabetes and kidney disease-relevant
IMI1, FP7 and US consortia, like SUMMIT, KIDNEYCONNECT, Syskid, CPROBE and C-Path, in an unprecedented search for new and better biomarkers for DKD, through a better understanding of the disease.

Jointly, the partners have access to vast and very relevant clinical cohorts and trials, state-of-the-art analysis and imaging techniques, novel model systems and the long-standing experience and networks to make this collaboration a success. By involving regulatory agencies throughout the project, BEAt-DKD aims at making the introduction and acceptance of new tools as efficient as possible.

The overall goals of BEAt-DKD are (1) to provide a holistic systems medicine view of the pathogenesis of DKD with the aim to identify targetable mechanisms and pathways underlying initiation and progression of DKD, applying a novel sub-classification of diabetes, and (2) to identify and validate biomarkers of disease progression and treatment responses representing first steps towards precision medicine in the management of DKD.

Coordinator

LUNDS UNIVERSITET

Address

Paradisgatan 5c
22100 Lund

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 110 937

Participants (30)

Sort alphabetically

Sort by EU Contribution

Expand all

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 800 000

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 2 100 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 900 000

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 200 000

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 655 000

THE UNIVERSITY OF EXETER

United Kingdom

EU Contribution

€ 555 000

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 150 000

TURUN YLIOPISTO

Finland

EU Contribution

€ 320 000

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 70 000

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 500 000

UNIVERSITY OF LEEDS

United Kingdom

EU Contribution

€ 860 000

UNIVERSITY OF HULL

United Kingdom

EU Contribution

€ 250 000

CHU HOPITAUX DE BORDEAUX

France

EU Contribution

€ 460 000

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 500 000

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Austria

EU Contribution

€ 895 000

KLINIKUM DER UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 360 000

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 950 000

UNIVERSITA DEGLI STUDI DI BARI ALDO MORO

Italy

EU Contribution

€ 620 000

LIPOTYPE

Germany

EU Contribution

€ 300 000

UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN

United States

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

JDRF INTERNATIONAL

United States

ABBVIE INC

United States

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

ASTELLAS PHARMA EUROPE BV

Netherlands

Eli Lilly and Company Limited

United Kingdom

Bayer Pharma AG

Germany

NOVO NORDISK A/S

Denmark

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 1 530 000

Project information

Grant agreement ID: 115974

Status

Ongoing project

  • Start date

    1 September 2016

  • End date

    31 August 2021

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 30 960 037

  • EU contribution

    € 15 085 937

Coordinated by:

LUNDS UNIVERSITET

Sweden